Profile

Bayard L. Powell, M.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

209 Ratings
23 Comments
 

Bayard L. Powell, M.D.

Section Chief,
Director-At-Large,
Professor,

Clinical Interests

Acute and Chronic Leukemia, Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Leukemia

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.S.E., Duke University, 1976
  • M.D., University of North Carolina School of Medicine, 1980
  • Residency, Internal Medicine, NC Baptist Hospital, 1983
  • Fellowship, NC Baptist Hospital, 1986

Board Certifications

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

Memberships

  • Am Coll Of Physicians
  • Am Soc of Clinical Oncology
  • Am Soc of Hematology
  • Assn Of Med Schl Professors Of
  • Cancer & Acute Leukemia Group

NPI Number

  • 1831173954
Bayard L. Powell, M.D.

Doctor Rating

4.8 out of 5

209 Ratings
23 Comments
 

Bayard L. Powell, M.D.

Section Chief, Hematology & Oncology
Director-At-Large, Comprehensive Cancer Center
Professor, Hematology & Oncology

Research Interests

Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents; MicroRNAs
More »

Contact Information

Academic: 336-716-7970 | Department: 336-716-4464

Media Medical Expert »

Recent Publications

Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: a pooled analysis from four CALGB (Alliance) clinical trials. Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM.. Am J Hematol. 2016;91(2):199-204.

Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD.. J Geriatr Oncol. 2016;7(1):24-31.

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D, Yoshida K, Ganesan S, Hattori N, Fulton N, Tan KT, Alpermann T, Kuo MC, Rostami S, Matthews J, Sanada M, Liu LZ, Shiraishi Y, Miyano S, Chendamarai E, Hou HA,.. Leukemia. 2016;30(8):1672-1681.

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Niederwieser C, Nicolet D, Carroll AJ, Kolitz JE, Powell BL, Kohlschmidt J, Stone RM, Byrd JC, Mrozek K, Bloomfield CD.. Haematologica. 2016;101(12):1516-1523.

Long non-coding RNA profiling provides important prognostic information and biologic insights in younger patients with cytogenetically normal acute myeloid leukemia (alliance/CALGB 8461, 9665, 20202) [abstract]. Papaioannou D, Nicolet D, Volinia S, Mrozek K, Yan P, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD.. Haematologica. 2016;101(Suppl 1):326.

CPX-351 treatment of previously untreated older AML patients with high risk AML markedly increases the response rate over 7+3 in patients with FLT3 mutations [abstract]. Lancet J, Uy G, Cortes J, Newell L, Lin T, Ritchie E, Strickland S, Stuart R, Hogge D, Solomon S, Stone R, Bixby D, Kolitz J, Schiller G, Wieduwilt M, Rao A, Rubenstein S, Stock W, Foster M, Erba H, Goldberg S, Powell B, Podoltsev N, Atallah E,.. Haematologica. 2016;101(Suppl 1):186.

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wang ES, Hoke E, Mrozek K, Kohlschmidt J, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA.. Leukemia. 2016;():.

Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB.. J Am Geriatr Soc. 2016;64(10):1988-1995.

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R,.. Leukemia. 2015;29(3):567-575.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL.. Blood. 2015;125(9):1367-1376.

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B.. J Clin Oncol. 2015;33(11):1252-1257.

Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donor. Palanisamy A, Persad P, Koty PP, Douglas LL, Stratta RJ, Rogers J, Reeves-Daniel AM, Orlando G, Farney AC, Beaty MW, Pettenati MJ, Iskandar SS, Grier DD, Kaczmorski SA, Doares WH, Gautreaux MD, Freedman BI, Powell BL.. Case Rep Nephrol. 2015;2015():821346.

High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS.. Leuk Res. 2015;39(9):945-949.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L,.. Lancet Oncol. 2015;16(9):1025-1036.

Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. J Clin Oncol. 2015;33(15 Suppl):7015.

Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (Alliance C11001) [abstract]. Uy GL, Mandrekar S, Laumann K, Sanford B, Marcucci G, Zhao WQ, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Bloomfield CD, Byrd JC, Stone RM, Larson RA.. Blood. 2015;126(23):319.

The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL.. Blood. 2015;126(23):2556.

Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R [abstract]. Dunleavy K, Noy A, Abramson JS, LaCasce AS, Link BK, Parekh S, Jagadeesh D, Bierman PJ, Mitsuyasu RT, Battini R, Watson PR, Peace D, Averbrook BJ, Naina HV, Leach JW, Hanna WT, Powell BL, Nagpal S, Roschewski M, Lucas AN, Steinberg SM,.. Blood. 2015;126(23):342.

North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults. Foran JM, Sun ZX, Claxton DF, Lazarus HM, Thomas ML, Melnick A, Levine RL, Paietta E, Arber D, Zhang YM, Rowe JM, Godwin JE, Altman JK, Luger S, Al-Kali A, Zheng H, Pratz K, Broun ER, Powell BL, O'Dwyer K, Litzow MR, Tallman MS.. Blood. 2015;126(23):217.

Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S.. Blood. 2015;126(23):2102.

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T.. Ann Hematol. 2014;93(1):47-55.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrozek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bar C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE,.. J Clin Oncol. 2014;32(6):548-556.

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA.. Br J Haematol. 2014;165(1):102-111.

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA.. Haematologica. 2014;99(1):111-115.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrozek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD.. Leukemia. 2014;28(6):1252-1258.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.. Br J Haematol. 2014;165(4):497-503.

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA.. Cancer. 2014;120(7):1010-1017.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 [letter]. Becker H, Maharry K, Mrozek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D,.. Leukemia. 2014;28(8):1754-1758.

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Poire X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W.. Leuk Lymphoma. 2014;55(7):1523-1532.

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD.. Leuk Res. 2014;38(10):1184-1190.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2014;20(20):5255-5264.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrozek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM,.. Proc Natl Acad Sci U S A. 2014;111(52):18679-84.

miR-3151 interplays with its host gene BAALC and independently impacts on outcome of older patients with cytogenetically normal acute myeloid leukemia by direct deregulation of TP53 [abstract]. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA,.. Clin Lymphoma Myeloma Leuk. 2014;14(Suppl 3):S157.

Effect of young age on outcomes in pediatric acute promyelocytic leukemia (APL): North American Intergroup Study CALGB 9710 (alliance) [abstract]. Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH.. Blood. 2014;124(21):2301.

A comparison of outcomes between adolescents and young adults (AYA) and children with acute promyelocytic leukemia (APL): North American Intergroup Study CALGB 9710 (alliance) [abstract]. Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH.. Blood. 2014;124(21):2306.

Obesity does not affect the recurrence free survival rates in children less than 20 years of age in acute promyelocytic leukemia (APL) [abstract]. Lee JH, Rademaker AW, Powell BL, Geyer S, Larson RA, Gregory J, Hijiya N, Feusner JH.. Blood. 2014;124(21):957.

Telomere length recovery strongly predicts overall survival in acute promyelocytic leukemia [abstract]. Baljevic M, Dumitriu B, Lee JW, Paietta E, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Young NS, Tallman MS.. Blood. 2014;124(21):2375.

Increasing clinical trials accrual at a Comprehensive Cancer Center [abstract]. Powell BL, Olson D, Morrell RM, Hales TL, High KP, Abraham E.. Blood. 2014;124(21):1266.

The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL.. Blood. 2014;124(21):3744.

A longitudinal investigation of posttraumatic growth in adult patients undergoing treatment for acute leukemia. Danhauer SC, Russell GB, Tedeschi RG, Jesse MT, Vishnevsky T, Daley K, Carroll S, Triplett KN, Calhoun LG, Cann A, Powell BL.. J Clin Psychol Med Settings. 2013;20(1):13-24.

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrozek K, Bloomfield CD, Larson RA.. Cancer. 2013;119(1):90-98.

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA.. J Clin Oncol. 2013;31(7):923-929.

Acute promyelocytic leukemia: progress far and wide [comment]. Powell BL.. Blood. 2013;121(11):1925-1926.

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL.. Blood. 2013;121(21):4287-4294.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD.. J Clin Oncol. 2013;31(17):2086-2093.

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD.. Leukemia. 2013;27(10):2023-2031.

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Nicolini FE, Turkina A, Shen Z-X, Gallagher N, Jootar S, Powell BL, De Souza C, Zheng M, Szczudlo T, le Coutre P.. Cancer. 2012;118(1):118-126.

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA,.. J Clin Oncol. 2012;30(7):742-750.

Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A.. Leuk Lymphoma. 2012;53(5):907-914.

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH.. Haematologica. 2012;97(5):739-742.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Acute and Chronic Leukemia, Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies, Leukemia
Bayard L. Powell, M.D.

Bayard L. Powell, M.D.

Section Chief, Hematology & Oncology
Director-At-Large, Comprehensive Cancer Center
Professor, Hematology & Oncology

Doctor Rating

4.8 out of 5

Bayard L. Powell, M.D.209 Ratings
23 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.9
CP explanations of prob/condition
4.9
CP spoke using clear language
4.9
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
3.9



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

10/22/2016

excellent care. do not know where they could improve.

10/6/2016

Great staff & doctors.

9/25/2016

excellent

9/22/2016

The experience I've had with *Dr. Bayard has been unquestionable. #10. 100%.

9/20/2016

Dr. Powell is wonderful! Routine f/u appointments every 6 months. I have been a patient for 10 + years

9/19/2016

I thank God for Dr Powell. He's doing a great job if you ask me. Very knowledgeable. in the field of leukemia.

8/22/2016

*Dr. Powell is an exceptional doctor - the very best!

7/29/2016

I have absolutely been blessed by *Dr. Powell & his team. I couldn't be more pleased with the level of care and concern they have shown me.

7/20/2016

*Dr. Powell and his PA were very compassionate and caring. Everything was explained thoroughly and all questions were addressed.

7/16/2016

Dr Powell is great doctor.NP Megan is great too.They are very caring, professional care givers.

6/22/2016

I have never had a bad experience with Dr. Powell or anyone in his department. I have the utmost confidence in them.

6/17/2016

*Dr. Powell is one of the bet doctors I have seen.

5/25/2016

Dr Bayard Powell is the most exceptional physician I have ever known & I consider myself very lucky to have him by my side for the last 13 years.

5/17/2016

I simply love Dr. Powell and feel so blessed to be in his care. I have been seeing him since being diagnosed with CML and could not ask for a better doctor. He is the best as far as I am concerned.

5/4/2016

I trust Dr Powell and his staff with my life

3/29/2016

I would definitely recommend the Cancer Center there, which I already have.

3/24/2016

Excellent!

2/22/2016

*Dr. Powell is one of the best doctors that I have had. (THE BEST) ever.)

2/18/2016

Very good experience.

1/21/2016

*Dr. Powell & everyone in his department are exceptional in meeting my medical needs.

1/7/2016

______ I have never had a very bad experience always good.

1/1/2016

Dr. Powell and Lauren were both very informative and helpful about my medical problem.

12/20/2015

We feel very fortunate to see Dr. Powell & his PA's (Megan, Sarah and Susan) during our visits. All are top notch providers!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.